• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BAUSCH + LOMB BAUSCH + LOMB INJECTOR SYSTEM CARTRIDGE; FOLDERS AND INJECTORS, INTRAOCULAR LENS (IOL)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BAUSCH + LOMB BAUSCH + LOMB INJECTOR SYSTEM CARTRIDGE; FOLDERS AND INJECTORS, INTRAOCULAR LENS (IOL) Back to Search Results
Model Number BLIS-X1
Device Problems Adverse Event Without Identified Device or Use Problem (2993); Insufficient Information (3190)
Patient Problems Blurred Vision (2137); Vitrectomy (2643); No Code Available (3191)
Event Date 06/11/2020
Event Type  Injury  
Manufacturer Narrative
Though requested, the inserter was not returned for evaluation.A device history record review could not be performed as no lot number was provided.Based upon the complaint trend review this product is within the acceptable control limits and no complaint trends were observed.The risk analysis and directions for use review were considered acceptable, with the product performing within anticipated rates.A definitive root cause cannot be determined.The most probable root cause is operational context.The iol damage may have occurred if the user misaligned the injector cartridge between the hard plunger and iol when clicking the cartridge into the injector.No corrective action is necessary at this time.
 
Event Description
It was reported that an intraocular lens (iol) was explanted from the patient¿s eye approximately thirteen months post-implant due to a mark on the iol.The lens was explanted and replaced with a different model lens.The incision was enlarged and 10-0 nylon suture was used.No other patient impact was reported.Though requested, no additional information has been received.
 
Event Description
Further information indicates that the patient experienced blurred vision and post-operative myopia subsequent to the implant surgery, despite a visual acuity of 20/20.The patient noticed a decrease in their vision.The iol optic was not clear and free of debris and deposits, as the physician noticed a surface anterior central mark on the lens with paracentral opacity.The patient had one yag three months post-implant and one yag four months post-implant with no symptom resolution.A vitrectomy was performed during the explant surgery thirteen months postoperatively.The physician was unable to indicate a likely cause for the event.The patient¿s current prognosis and outcome is good.
 
Manufacturer Narrative
Although requested, the device was not return for evaluation.The findings reported in our previous submission remain unchanged.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
BAUSCH + LOMB INJECTOR SYSTEM CARTRIDGE
Type of Device
FOLDERS AND INJECTORS, INTRAOCULAR LENS (IOL)
Manufacturer (Section D)
BAUSCH + LOMB
1400 north goodman street
rochester NY 14609
MDR Report Key10868877
MDR Text Key217920431
Report Number0001313525-2020-00171
Device Sequence Number1
Product Code MSS
Combination Product (y/n)Y
PMA/PMN Number
K131958
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional,user faci
Type of Report Initial,Followup
Report Date 10/21/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberBLIS-X1
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Initial Date Manufacturer Received Not provided
Initial Date FDA Received11/19/2020
Supplement Dates Manufacturer ReceivedNot provided
Supplement Dates FDA Received12/17/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
ENVISTA IOL; PROVISC, ALCON BSS
Patient Outcome(s) Required Intervention;
Patient Age66 YR
-
-